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Pre-pregnant Prediction of Recurrent
Preeclampsia in Normotensive Thrombophilic
Formerly Preeclamptic Women Receiving
Prophylactic Antithrombotic Medication
Marc E. A. Spaanderman, MD, PhD, Robert Aardenburg, MD,
Timo H. A. Ekhart, BSc, Hugo W. F. van Eyndhoven, MD,
Peter W. de Leeuw, MD, PhD, and Louis L. H. Peeters, MD, PhD
BACKGROUND: Both hemodynamic abnormalities and thrombophilia predispose to pregnancy-associated
vascular complications such as fetal growth restriction, stillbirth, preeclampsia, and placental abruption.
Antithrombotic treatment may reduce the riskfor these events. In this study we tested the hypothesis that
in normotensive thrombophilicformerly preeclamptic women certain alterations in hemodynamicfunction as
measured under nonpregnant conditions predict the development ofhypertensive disorders and/orfetal growth
restriction in the subsequent pregnancy.
METHODS: In 350 nondiabeticformerly preeclamptic women, we measured in thefollicular phase of the
menstrual cycle at least 5 months postpartum central hemodynamic, metabolic, and hemostatic variables. In
the subsequent ongoing pregnancy we determined fetal outcome variables and the incidence of maternal
vascular cominplications. In addition to a nornotensive thrombophilic profile, inclusion for final analysis
required a subsequent singleton pregnancy, established within 1 yearfollowing the pre-pregnant evaluation
and ongoing beyond 16 weeks' gestation. As a consequence, 47 normotensive thrombophilic formerly
preeclamptic women could be includedforfinal analysis. Allformerlypreeclampticparticipants received aspirin
throughout pregnancy. Additionally, those with thrombophilia or hyperhomocysteinemia were treated with
low molecular weight heparin and with pyridoxine andfolic acid supplementation, respectively.
RESULTS: Among 350 formerly preeclamptic women, 266 (76%) vere nonnotensive and 84 (24%)
hypertensive. About hajf (140/266) of normotensiveformerly preeclamptic participants were thrombophilic. One
hundred eighteenformerly preeclamptic participants succeeded in establishing an ongoing pregnancy within 1 year.
From this subset offormerly preeclamptic women, 47 were normotensive thrombophilic; 23 remained normotenisive
(THROMB), whereas 24 developed at least gestational hypertension (COMPLITHROMB). Participants in
the latter subgroup were more obese than those remaining normotensive. In addition, thisformer subset ofwomen
had a higher vascular resistance index, and a lowerplasma volume and cardiac index. With respect tofetal outcome,
COMPLITHROMB gave birth to an infant with a lower birth weight relative to THROMB. Preeclamipsia
wvith or witlhout the hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome recurred in 26%
of the participants in the whole thrombophilic group, in vvhich a low pre-pregnant plasma volume and a raised
vascular resistance predisposedfor recurrent hypertensive disorders.
CONCLUSION: Pre-pregnant hemodynamic, metabolic, and clotting variables in formerly preeclamptic
women can predict hypertension in the subsequent pregnancy. (J Soc Gynecol Investig 2005; 12:
112-7) Copyright C) 2005 by the Societyfor Gynecologic Investigation.
KEY WORDS: Preeclampsia, plasma volume, recurrence, pre-pregnant, prediction, thrombophiha.
igh blood pressure complicates almost 10% of all
pregnancies.1'2 It is an important cause of perinatal
mortality and morbidity, as it predisposes for fetal
growth restriction and iatrogenic preterm birth. In recent
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years, evidence is accumulating that particularly preexisting
vascular, metabolic, or clotting disorders predispose to hyper-
tensive complications in pregnancy.3 8 The latter suggests that
in these cases the preexistent disorder predisposes for "endo-
thelial decompensation" in pregnancy, the common end point
of different pathogenetic pathways in pregnancy-related hy-
pertensive syndromes.9 Recently, we observed in formerly
preeclamptic women that a low plasma volume prior to preg-
nancy predisposes to recurrence of a hypertensive disorder in a
next pregnancy.8 Unfortunately, the predictive value of a
1071 -5576/05/$30.00
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 at Radboud Universiteit Nijmegen on July 12, 2012rsx.sagepub.comDownloaded from 
Prediction of Recurrent Preeclampsia J Soc Gynecol Investig Vol. 12, No. 2, February 2005 113
subnormal plasma volume was modest, probably because ges-
tational vascular complications may result from a wide variety
of hemodynamic, clotting, and mixed disorders. The latter
indicates that in formerly preeclamptic women, stratification
for potential underlying pathophysiologically distinct disorders
may improve the value of subnormal plasma volume and that
of other markers in predicting recurrence of hypertensive
disease and/or placental insufficiency in a next pregnancy.
Thrombophilia, a condition that predisposes to thrombo-
embolic disease, is associated with an increased risk for hyper-
tensive complications in pregnancy, including placental
insufficiency.3-6 10 Although antithrombotic prophylaxis in
these women may reduce the risk to develop these complica-
tions, it is unlikely to ameliorate concomitant nonthrombotic
risk conditions.'1
Taking a preexistent risk condition as a starting point,6 the
following questions may be addressed: First, what is the recur-
rence rate of hypertensive complications in a subsequent preg-
nancy for certain identifiable risk conditions? Second, is the
presence of more than one disorder associated with a higher
recurrence rate of hypertensive complications in pregnancy?
The objective of the present study was to test the hypothesis
that in normotensive thrombophilic formerly preeclamptic
women, hemodynamic, metabolic, and volume variables de-
termined before pregnancy are clinically relevant for predicting
recurrent hypertensive disorders and/or fetal growth restric-
tion in a next pregnancy. To this end, we determined in
formerly preeclamptic women, clotting function, central he-
modynamic variables, and plasma volume before the next
pregnancy. Then, we registered the recurrence rate of hyper-
tensive complications and/or fetal growth restriction in that
next pregnancy. Finally, we determined the predicted value of
each marker determined before that pregnancy. All participat-
ing thrombophilic women received, based on the underlying
disorder, prophylactic medication, either low molecular
weight heparins and/or piridoxine and folic acid.
METHODS
Selection of Patients
A total of 350 formerly preeclamptic, nondiabetic women
participated in this study. Data acquisition was initiated at least
5 months postpartum. Formerly preeclamptic women were
recruited from our outpatient clinic at the postpartum follow-
up. Preeclampsia (gestational), hypertension, and the syndrome
of hemolysis, elevated liver enzymes, and low platelets
(HELLP) were defined according to the criteria of the Na-
tional High Blood Pressure Education Program Working
Group Report on High Blood Pressure in Pregnancy.I We
defined fetal growth restriction on the basis of the birth of a
baby with a neonatal birth weight below the tenth centile
according to Dutch centiles set by Kloosterman. Measurement
of the 24-hour urinary sodium output on the day before the
experiment was performed to estimate sodium intake. None of
the participants used vitamin supplements or any other medi-
cation in the 2 weeks before measurement. Women on anti-
women with a history of
preeclampsia
I(n=350)
hypertension normotension
(n=84) (n=266)
Ineither thirombophilia thrombophilia
nor hypertension
(n=126)
non-pregnant
(n=93)
(n=140)
I
pregnant
(n=47)
I
normotensive hypertensive
(n=23) (n=24)
Figure 1. Management, subdivision, and treatment of formerly pre-
eclamptic participants.
hypertensive drugs discontinued this medication at least 1
week prior to the study session. After an overnight fast, par-
ticipants were tested for thrombophilia, and hemodynamic and
metabolic function. Thrombophilia was defined as a condition
characterized by the presence of at least one clotting disorder
known to be associated with an increased risk of venous
thromboembolism. Inclusion for final analysis required the
establishment of an ongoing (>16 weeks' gestational age)
singleton pregnancy within 1 year after the pre-pregnant mea-
surements in a normotensive thrombophilic formerly preeclamp-
tic women. As a consequence, 47 formerly preeclamptic women
could be included for final analysis. After the measurement
sessions, formerly preeclamptic women were managed as illus-
trated in Figure 1. All subjects were Caucasian. Those who
smoked refrained from smoking during pregnancy. All partic-
ipants gave written informed consent. The hospital's medical
ethical committee approved the study.
Experimental Procedure
The methodology of the measurements and calculations with
respect to the thrombophilic screening and hemodynamic
function have been detailed elsewhere.6
THROMBOPHILIC SCREENING. In short, we measured
the presence oflupus anticoagulant and anticardiolipin antibodies.
We defined the antiphospholipid syndrome as the condition
where the titers of the circulating anticardiolipin antibodies were
Preeciampsia J Soc Gynecol Investig Vol. 12, No. 2, February 2005 113
 at Radboud Universiteit Nijmegen on July 12, 2012rsx.sagepub.comDownloaded from 
114 J Soc Gynecol Investig Vol. 12, No. 2, February 2005 Spaanderman et al
Table 1. Demographic Data From the Two Subgroups of
Formerly Preeclamptic Women
THROMB COMPLITHROMB
(n = 23) (n= 24)
Age (y) 29 (24-35) 28 (16-34)
Height (cm) 170 (154-183) 170 (157-180)
Body mass index
(kg m-2) 22 (19-33) 26 (19-36)*
Parity 1 (1-2) 1 (1-3)
Sodium excretion
(mmol 24 h 1) 107 (39-166) 125 (67-297)
P < .05.
higher than 15 GPL for IgG antiphospholipid antibodies and 20
MPL for IgM antiphosphohpid antibodies. Coagulation tests were
performed after a venous puncture. After ehlmination of platelets,
samples were stored at -80C prior to assay. In these samples we
determined protein C activity, total protein S antigen and free
protein S, activated protein C resistance, and antithrombin activ-
ity. A methionine-loading test was used to diagnose hyperhomo-
cysteinemia. During the test participants consumed a standard
low-methionine breakfast and lunch.
MEASUREMENT OF CENTRAL HEMODYNAMIC
FUNCTION. In the midfollicular phase (day 5 + 2) of the
menstrual period the measurement session started at 9 AM after
sampling of the clotting variables. Participants did not drink
caffeine- or alcohol-containing beverages and refrained from
smoking and eating for at least 10 hours before the experiment.
Throughout the measurement session, subjects were in half-
supine position on a comfortable chair. Arterial blood pressure
and heart rate were recorded intermittently by a semiautomatic
oscillometric device (Dinamap Vital Signs Monitor 1846;
Critikon, Tampa, FL), interrupted only during blood sam-
pling. Urinary sodium concentration was measured in a urine
sample collected over the 24 hours preceding the measurement
session. All variables were measured by standard chemical
procedures.
MEASUREMENT OF PLASMA VOLUME. Plasma vol-
ume was measured using the iodine 125-albumin (1251-HSA)
indicator dilution method and expressed in milliliters per ki-
logram (mL/kg) lean body mass (LBM).6
ECHOCARDIOGRAPHY. Echocardiography (ECG) to as-
sess cardiac function was performed in the semi-left lateral
position, after completion of the plasma volume measurement
and after 5 minutes rest, using a cross-sectional, phased-array
ECG Doppler system (Hewlett-Packard Sonos 2500, Andover,
MA.6
Cardiac output (L min-1) was calculated by multiplying
stroke volume (mL) and heart rate (bpm). In this formula, heart
rate was obtained by taking the reciprocal of the mean of five
consecutive R-R intervals on the ECG. Stroke volume was
calculated by multiplying the aortic velocity integral and the
aortic area. Aortic flow was measured across the aortic valves
from an apical approach.6 Total peripheral vascular resistance
(dyne s cm- ) and index (dyne s cm-5 m-2) were
obtained by taking the quotient, respectively, of mean arterial
pressure and cardiac output and cardiac index. The values used
for mean arterial pressure were obtained during the cardiac
output measurement using the recordings of the Dinamap
apparatus and were calculated as the mean of three consecutive
recordings.
STATISTICAL ANALYSIS. Data are presented as medians
and ranges unless stated othervise. Intragroup differences were
tested with the Wilcoxon signed-ranks matched-pairs test, and
differences between groups with the Mann-Whitney U test.
Correlations, when calculated, between concomitantly mea-
sured potentially related variables, were tested by Spearman
rank correlation analysis. A P value less than .05 was considered
statistically significant. We peiformed a multivariate backward
stepwise logistic regression analysis that included as dependent
variables only those that were found to be correlated between
the recurrence of gestational hypertension and preeclampsia,
and maternal hemodynamic variables. This analysis allowed us
to identify actual independent predictors of maternal hyper-
tensive complications. From the independent predictors, we
calculated the Mantel-Haenszel common odds ratio and 95%
confidence interval. Finally, the calculated minimum detect-
able differences of the mean of variables within the thrombo-
philic group (n 47, a = 0.05, p3 = 0.10), assuming a normal
distribution of the data, were 1 1% for body mass index, 6% for
mean arterial pressure, 8% for heart rate, 9% for plasma vol-
ume, 11% for cardiac output, 9% for cardiac index, 11% for
total peripheral vascular resistance and its index, 3 weeks in
gestational age at delivery, 595 g in birth weight, and a differ-
ence of 15 in centile, respectively.
RESULTS
Of the 350 eligible formerly preeclamptic participants, 47
normotensive thrombophilic formerly preeclamptic women
were available for final analysis. Thirty-eight thrombophilic
formerly preeclamptic women had one thrombophilic disor-
der, and nine had more than one. Twenty-four of 47 devel-
oped at least gestational hypertension. They were assigned to
Table 2. Hemodynamic and Vascular Data
THROMB COMPLITHROMB
(n = 23) (n 24)
Mean arterial pressure
(mmHg) 87 (72-97) 86 (77-101)
Heart rate (bpm) 67 (44-87) 62 (48-83)
Cardiac output
(L mn- 1) 5.3 (4.1-8.2) 5.4 (3.9-6.9)
Cardiac index
(L -mmn1 M-2) 3.2 (2.6-4.3) 2.9 (2.2-3.4)*
TPVR
(X102 dyne s cm-5) 13 (8-16) 14 (10-17)
TPVR index (X 102 dyne
s cm 5 m 2) 21 (13-27) 25 (19-31)*
Plasma volume
(mL 1kgLBM) 53 (43-59) 45 (25-54)*
TPVR = total penrpheral vascular resistance.
* p < .05.
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Table 3. Maternal Pregnancy Outcome
Previous Current
Group pregnancy n (%) pregnancy n (%)
Gestational hypertension THROMB 23 (100%) 0 (0%)*
COMPLITHROM 24 (100%) 24 (100%)
Preeclampsia THROMB 23 (100%) 0 (0%)*
COMPLITHROM 24 (100%) 12 (50%)* I
HELLP syndrome THROMB 14 (61%) 0 (0%) *
COMPLITHROM 12 (50%) 12 (50%) 4
Gestational age PE/HELLP (wk) THROMB 29 (22-39)
COMPLITHROM 28 (23-38) 36 (21-39)*
An arrow indicates a difference between both groups.
HELLP syndrome = hemolysis, elevated liver enzymes, low platelets; PE = preeclampsia.
* Indicates the value is different from the previous pregnancy within the same subgroup (P < .05).
the COMPLITHROMB group. Those who remained nor- Table 2 lists the cardiovascular data and plasma volume. In
motensive throughout pregnancy were assigned to the COMPLITHROMB, total peripheral vascular resistance in-
THROMB group. The demographic characteristics of in- dex was higher, and plasma volume and cardiac index lower,
cluded participants are listed in Table 1. The two subgroups of than in THROMB.
normotensive thrombophilic formerly preeclamptic women Maternal and fetal data with respect to the preceding and
and the controls were comparable with respect to age, height, subsequent pregnancies are listed in Tables 3 and 4, respec-
parity, and urinary sodium output. COMPLITHROMB were tively. Most of the outcome variables in the two formerly
more obese than THROMB. preeclamptic subgroups had improved markedly in the subse-
Among the formerly preeclamptic women, the antiphos- quent pregnancy relative to the preceding pregnancy. None-
pholipid syndrome (13/47, 28%) and hyperhomocysteinemia theless, COMPLITHROMB had a higher incidence of fetal
(24/47, 51%) were most common, followed by protein S growth restriction as indicated by lower birth weight and
deficiency (11/47, 23%), activated protein C resistance as a centile. In the whole group, as compared to the preceding
consequence of factor V Leiden mutation (6/47, 13%) and complicated pregnancy, we noted a 7-week (0 to 15) prolon-
protein C deficiency (1/47, 2%). Nine formerly preeclamptic gation of pregnancy, which contributed to an increase in
women, who were diagnosed as having the antiphospholipid neonatal weight by 1880 g (-220 to 3210) corresponding with
syndrome, were IgG serotypes. We did identify one woman an increase in birth weight centile 12 (-45 to 88). If in these
with antithrombin deficiency. Between evaluation and subse- formerly preeclamptic women the subsequent pregnancy was
quent ongoing pregnancy, 10 of 47 (21%) formerly preeclamp- complicated by recurrent preeclampsia, the complication de-
tic thrombophilic women experienced a spontaneous abortion, veloped approximately 7 weeks (-5 to 14) later than in the
six in conjunction with hyperhomocysteinemia (one with an preceding index pregnancy. Pre-pregnant plasma volume cor-
antiphospholipid syndrome as well), two in conjunction with related inversely with the recurrence rate of gestational hyper-
protein S deficiency, and two with an antiphospholipid syn- tension (r = -0.67, P <.0001), preeclampsia (r = -0.64,
drome. There were no differences between type of thrombo- P <.0001), and HELLP syndrome (r = -0.37, P = .01). In
philic disorder and the recurrence of hypertensive addition, a low plasma volume predisposed to a lower gesta-
complications. tional age at delivery (r -0.31, P = .04). A receiver
Table 4. Fetal Pregnancy Outcome
Previous Current
Group pregnancy n (%) pregnancy n (%)
Gestational age at delivery (wk) THROMB 31 (24-39) 39 (35-41)*
COMPLITHROMB 30 (24-39) 38 (26-41)* 4
Prematurity THROMB 19 (82%) 1 (4%) *
COMPLITHROMB 22 (92%) 5 (21%)* I
Birth weight (g) THROMB 1170 (195-3260) 3440 (2330-4240)*
COMPLITHROMB 980 (335-3720) 3000 (480-3780)* 4
Centile THROMB 15 (1-70) 44 (4-95)*
COMPLITHROMB 5 (1-90) 4 25 (2-96)*4
Fetal growth Restriction THROMB 6 (26%) 5 (22%)
COMPLITHROMB 14 (58%) T 6 (25%)*
Stillbirth THROMB 5 (225%) 0 (0%)*
COMPLITHROMB 6 (250o) 0 (Oo)*
An arrow indicates a difference between both groups.
* Indicates the value is different from the previous pregnancy within the same subgroup (P < .05).
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Figure 2. Receiver operating characteristic curve f
tional hypertension (GH) (solid linie, solid circles) and pre
(dotted line, open circles) as a function of plasma volume
bophilic formerly preeclamptic women. *GH: PV
LBM-'; sensitivity = 100%, specificity = 74%, posi
value = 80%, negative predictive value = 100%. * PE
kg LBM-1: sensitivity = 83%, specificity = 100%, F
tive value = 100%, negative predictive value = 95%.
operating characteristic (ROC) curve to explore t
potential of the pre-pregnant plasma volume r
indicated that normotensive thrombophilic fP
eclamptic participants with a plasma volume belo
LBM- 1 were at high risk to develop recurrence
sia in a subsequent pregnancy, with a sensitivity a
of 83% and 100%, respectively. The associated
negative predictive values were 100% and 95%
(Figure 2). Almost 80% of this population (37/47,
volume of at least 42 mL kg LBM Two of
(5%) developed recurrent preeclampsia. Both
suffering from the antiphospholipid syndrome.
over the whole population, there was no correla
the type of thrombophilia and pregnancy outcoi
volume below 49 mL kg LBM 1 identified t]
women destined to develop gestational hyperte
sensitivity and specificity of 100% and 74%, and
negative predictive values of 80% and 100%, resp
ure 2). In addition, we performed a multivari;
logistic regression analysis in which body mass i
volume, cardiac index, and total peripheral vasci
index were included. After analysis, for recurre
hypertension, plasma volume (P = .002) and to
vascular resistance index (P = .047) appeared tc
dent risk factors, while in recurrent preeclampsia
volume remained an independent variable (P =
the multivariate analysis, a regression score was co
which a formula was constructed to predict reci
tensive complications. Comparing the predicted
problems as a function ofobserved hypertensive c
/' ' total peripheral vascular resistance did not contribute to better
/ predictive power. Therefore, only plasma volume was used to
compute recurrence risks. The common odds ratio on hyper-
tensive complications varied as a function of plasma volume
(Table 5).
The chance to develop recurrent gestational hypertension
can be calculated according to the formula: Pgestatnonal hypertension
1/1 + e- (15.967 - 0.33 PVLBM) The chance to develop recur-
rent preeclampsia can be calculated according to the formula:
Ppreeclampsia 1/l + e (23.551 - 0.547 PVLBM)
DISCUSSION
Although the underlying pathogenetic mechanisms of pre-
eclampsia are still unclear, there is general agreement about a
central role for throphoblastic factors and dysfunctional endo-
thelium in triggering the typical clinical symptoms.9 Tropho-
80 100 blastic and endothelial function can be jeopardized by
numerous factors, either biochemically, such as in thrombo-
hr both gesta- philia or diabetes mellitus, or mechanically, such as in hyper-
-eclampsia (PE) tension. Normal pregnancy is associated with a physiologic rise
among throm- in the strain exerted on the endothelium. Therefore, it is not
49 mL kg that risk factors enhance the devel-
itive predictive
tPV 42 mL opment of vascular complications during pregnancy. In this
ositive predic- prospective study, preexistent maternal features with extra
endothelial strain as common denominator were found to
predispose for recurrent hypertensive disorders in high-risk
he predictive pregnancies.
measurements With respect to the demographic characteristics, except for
ormerly pre- a higher body mass index in the COMPLITHROMB group,
lw 42 mL kg the two formerly preeclamptic subgroups did not differ appre-
oifpreeclamp- ciably. A higher body mass index in formerly preeclamptic
tnd specificity women has also been reported by others and is a well-known
positive and risk factor for both cardiovascular and metabolic complica-
respectively tions.12 There is substantial variation in reported incidences of
had a plasma thrombophilia among formerly preeclamptic women among
these women different geographic regions in the world. However, the in-
women were creased incidence of thrombophilic disorders among the for-
Nonetheless, merly preeclamptic individuals in this study is in line with
ttion between previous findings in Israeli and Dutch populations.3-5
me. A plasma Most previous studies on recurrence of hypertensive disor-
hrombophilic ders in pregnancy are based on obstetrical history as a starting
nsion with a point, rather than underlying disorders. Furthermore, most of
I positive and these studies were performed retrospectively, in untreated
)ectively (Fig-
ate backward Table 5. Risk of Recurrent Hypertensive Complications as a
ndex, plasma
alar resistance
nt gestational
tal peripheral
be indepen-
, only plasma
.002). From
mputed, after
urrent hyper-
hypertensive
omplications,
Function of Plasma Volume
Plasma volume OR 95% CI
Gestational hypertension
Plasma volume > 49 mL kgLBM 1 Reference
PV ' 49 mL kgL3M 1 32.6 5.8-181.7
PV ' 44 mL kgLBM0 34.0 4.9-235.6
Preeclampsia
Plasma volume > 49 mL kgLBM 1 Reference
PV < 49 mL kgLBMI 11.0 1.3-94.3
PV ' 44 mL kgLBM- 36.0 3.7-352.6
OR = odds ratio; CI = confidence interval; PV plasmia volume.
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women, and in a different geographically localized population.
Nevertheless, among normotensive formerly preeclamptic
women, the reported recurrence rate of preeclampsia in a
subsequent pregnancy ranged from 32-55%.13-5 Normoten-
sive women with a history ofHELLP syndrome had recurrent
preeclampsia and HELLP syndrome in 19-23% and 3-27%,
respectively.'6"7 In addition, with respect to gestational age,
subsequent HELLP pregnancies lasted on the average 2 weeks
longer than the preceding pregnancy.16 In our study, both
preeclampsia and HELLP syndrome recurred in 26% of the
formerly preeclamptic participants. However, clinically it is
important to consider this recurrence rate in the context of a
milder course of the recurrent disease as indicated by its later
onset and the substantially higher birth weight and correspond-
ing birth weight centile.
In thrombophilic formerly preeclamptic women, the recur-
rence rate of vascular complications was closely linked to a low
plasma volume, the most characteristic feature of a (latent)
hypertensive hemodynamic phenotype.6 More explicitly, if
plasma volume exceeded 49 mL/kg LBM, which was the case
in 34% of the normotensive thrombophilic formerly pre-
eclamptic population, preeclampsia and HELLP syndrome did
not recur. Plasma volume seems to provide an index of car-
diovascular adaptive capacity. Low values for this parameter
may therefore indicate a diminished capacity to meet the
increased blood flow demands of pregnancy, which, in some
cases, can be expected to lead to hemodynamic maladaptation
and with it the development ofhypertensive complications and
fetal growth restriction.
The present study was not designed to prove the efficacy of
low molecular weight heparin and/or vitamin supplementa-
tion in reducing the recurrence risk of hypertensive compli-
cations in pregnancy in formerly preeclamptic women with a
thrombophilic phenotype. Nevertheless, in thrombophilic for-
merly preeclamptic women, recurrent gestational hyperten-
sion, preeclampsia, HELLP syndromie, and growth restriction
seem to be related to the latent hypertensive profile rather than
the underlying thrombophilia. Therefore, our data indicate
that a prospective randomized study designed to evaluate the
efficacy of this prophylactic regimen might benefit from the
consideration that concomitantly reduced vascular reserves can
interfere with the study results. The results of the present study
suggest that insight into the hemodynamic and clotting func-
tions add an extra dimension to the counseling ofwomen with
a history of severe vascular complications in a preceding
pregnancy.
In conclusion, pre-pregnant hemodynamic and hemostatic
vanables in formerly preeclamptic women predict recurrent
hypertensive complications in a subsequent pregnancy.
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